TABLE 2.

Baseline Characteristics and Response to L-thyroxine Treatment of Congenital Hypothyroidism

	Patient 1	Patient 2	Patient 3
Gender	Male	Female	Male
At Diagnosis
Age (y)	14.8	7.7	0.5
Height (SD)	−7.5	−8.1	−8.1
Weight (SD)	−11.3	−7.3	−3.7
Bone age (y, SDS)	(1.3, −13.5)	(0.8, −8.6)	—
IGF-1 (SD)	−1.4a	—	—
IGFBP-3 (SD)	−2.3	—	—
Tanner stage (breasts)	N/A	1	N/A
Tanner stage (testes)	1	N/A	1
Tanner stage (pubic hair)	1	1	1
Testicular vol (mL)	2	N/A	2
TSH (mU/L)	150	>500	26
FT4 (ng/dL)	Not available	0.36	0.89
At Most Recent Visit 8 y After the Diagnosis and Treatment of CH
Age (y)	22	15	8
Height (SD)	−5.2	−2.1	−1.3
Δ height (SDS)	2.3	6.0	6.8
Wt (SD)	−4.7	−2.4	−2.5
Bone age (y, SDS)	(14, −6.2)	(14.5, −0.3)	7.4
IGF-1 (SD) (on GH therapy)	0.5b	−1.7	—
IGFBP-3 (SD)	−1.6	−2.7	—
Tanner stage (breasts)	N/A	4	N/A
Tanner stage (testes)	3	N/A	1
Tanner stage pubic hair	4	3	1
Testicular vol (mL)	12	N/A	2
TSH (mU/L)	3.86	2	4.41
FT4 (ng/dL)	0.96	1.03	1.31

FT4, free thyroxine; IGF-1, insulin-like growth factor-1; N/A, not applicable; SDS, SD score.

^aBefore GH therapy.

^bOn GH therapy.